» Articles » PMID: 25826076

Decreased MiR122 in Hepatocellular Carcinoma Leads to Chemoresistance with Increased Arginine

Abstract

Reduced expression of microRNA122 (miR122), a liver-specific microRNA, is frequent in hepatocellular carcinoma (HCC). However, its biological significances remain poorly understood. Because deregulated amino acid levels in cancers can affect their biological behavior, we determined the amino acid levels in miR122-silenced mouse liver tissues, in which intracellular arginine levels were significantly increased. The increased intracellular arginine levels were through upregulation of the solute carrier family 7 (SLC7A1), a transporter of arginine and a direct target of miR122. Arginine is the substrate for nitric oxide (NO) synthetase, and intracellular NO levels were increased in miR122-silenced HCC cells, with increased resistance to sorafenib, a multikinase inhibitor. Conversely, maintenance of the miR122-silenced HCC cells in arginine-depleted culture media, as well as overexpression of miR122 in miR122-low-expressing HCC cells, reversed these effects and rendered the cells more sensitive to sorafenib. Using a reporter knock-in construct, chemical compounds were screened, and Wee1 kinase inhibitor was identified as upregulators of miR122 transcription, which increased the sensitivity of the cells to sorafenib. These results provide an insight into sorafenib resistance in miR122-low HCC, and suggest that arginine depletion or a combination of sorafenib with the identified compound may provide promising approaches to managing this HCC subset.

Citing Articles

Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications.

Park S, Hall M Exp Mol Med. 2025; .

PMID: 40025169 DOI: 10.1038/s12276-025-01415-2.


Target miRNA identification for the LPL gene in large yellow croaker (Larimichthys crocea).

Ullah K, Hossain A, Cao M, Xue L, Wang Y Sci Rep. 2025; 15(1):4164.

PMID: 39905090 PMC: 11794633. DOI: 10.1038/s41598-024-82988-2.


Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Gawi Ermi A, Sarkar D Cancers (Basel). 2024; 16(23).

PMID: 39682130 PMC: 11640171. DOI: 10.3390/cancers16233944.


Glycosyltransferase B4GALNT1 promotes immunosuppression in hepatocellular carcinoma via the HES4-SPP1-TAM/Th2 axis.

Wang Z, Liu J, Wang X, Wu Q, Peng Q, Yang T Mol Biomed. 2024; 5(1):65.

PMID: 39616302 PMC: 11608210. DOI: 10.1186/s43556-024-00231-w.


MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.

Guo J, Zhong L, Momeni M Cell Biol Toxicol. 2024; 40(1):77.

PMID: 39283408 PMC: 11405467. DOI: 10.1007/s10565-024-09920-2.


References
1.
Burns D, DAmbrogio A, Nottrott S, Richter J . CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature. 2011; 473(7345):105-8. PMC: 3088779. DOI: 10.1038/nature09908. View

2.
Lanford R, Hildebrandt-Eriksen E, Petri A, Persson R, Lindow M, Munk M . Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2009; 327(5962):198-201. PMC: 3436126. DOI: 10.1126/science.1178178. View

3.
Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M . MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011; 2:338. DOI: 10.1038/ncomms1345. View

4.
Negrini M, Gramantieri L, Sabbioni S, Croce C . microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem. 2011; 11(6):500-21. DOI: 10.2174/187152011796011037. View

5.
Eyler C, Wu Q, Yan K, MacSwords J, Chandler-Militello D, Misuraca K . Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011; 146(1):53-66. PMC: 3144745. DOI: 10.1016/j.cell.2011.06.006. View